Lymphoma Hub

During the Lymphoma Hub Steering Committee Meeting, Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US, chaired a discussion on cereblon E3 ligase modulators (CELMoDs) for the treatment of non-Hodgkin lymphoma. This discussion also featured Grzegorz Nowakowski, Sonali Smith, Ulrich Jäger, Catherine Thieblemont, Michael Dickinson, Francesc Bosch, Miles Prince, and Marek Trněný. Pri...

During the 18th International Conference on Malignant Lymphoma (ICML), Jun 17–21, 2025, Lugano, CH, the Lymphoma Hub was pleased to speak with Juan Pablo Alderuccio, University of Miami, Florida, US. We asked, What do the initial results from the LOTIS-7 (NCT04970901) trial suggest for loncastuximab tesirine plus glofitamab in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)?  ...

During the 18th International Conference on Malignant Lymphomas (ICML), Jun 17–21, 2025, Lugano, CH, the Lymphoma Hub was pleased to speak with Joshua Brody from the Icahn School of Medicine at Mount Sinai, New York, US. We asked about the clinical significance of the long-term results from the  EPCORE NHL-2  ( NCT04663347 ) trial, which evaluated  epcoritamab  (epcor) in combi...

This educational resource is independently supported by Roche. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.  During the 30th European Hematology Association (EHA) Congress, the Lymphoma Hub was pleased to speak to Gareth Gregory, Monash University, Melbourne, AU. We asked about the latest...

This educational resource is independently supported by AbbVie. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.  During the 30th European Hematology Association (EHA) Congress, the Lymphoma Hub was pleased to speak to Marek Trněný, Charles University, Prague, CZ. We asked, How effective is ep...

The Lymphoma Hub was pleased to speak to Grzegorz S. Nowakowski, Mayo Clinic, Rochester, US, who discussed the real-world experience of tafasitamab and lenalidomide for the treatment of relapsed/refractory diffuse large B-cell lymphoma.    This educational resource is independently supported by Incyte. All content is developed by SES in collaboration with an expert steering committee; fu...

This educational resource is independently supported by Incyte. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.     Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US, discusses the evolving treatment landscape for relapsed/refractory diffuse large B-cell lymphoma, focus...

During the 66th American Society of Hematology (ASH) Meeting and Exposition, the Lymphoma Hub was pleased to speak to Stefano Luminari, University of Modena and Reggio Emilia, Modena, IT. We asked about the latest updates from the inMIND trial of tafasitamab plus lenalidomide and rituximab for R/R FL.   In this interview, Luminari shares data from the phase III inMIND (NCT04680052) trial of p...

During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint satellite symposium entitled: Sequencing immune-based therapies in B-cell malignancies. Here, the Lymphoma Hub is pleased to share a real-world patient case, real-world evidence and experience, and treatment optimization of chimeric antigen receptor (CAR) T-cell therapy in...

During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub was pleased to speak to Paolo Ghia, Vita-Salute San Raffaele, Milan, IT. We asked about the latest updates from the SEQUOIA trial of zanubrutinib + venetoclax in treatment-naïve patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).  In this interview, Paolo Ghia shares data...

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US. We asked for an update on the SYMPHONY 1 trial ( NCT04224493 ).   First, Salles explains the rationale for using tazemetostat, an oral EZH2 inhibitor, with lenalidomide and rituximab in the phase Ib SYMPHONY 1 trial...

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Chan Cheah, University of Western Australia, Perth, AU. We asked for an update on novel therapies in chronic lymphocytic leukemia (CLL).   Cheah reviews the abstracts that were presented at ASH on novel BTK inhibitors and Bcl-2 inhibitors for relapsed/refractory CLL. This includes an...

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Pere Barba, Hospital Universitari Vall d'Hebron, Barcelona, ES. We asked, What are the chimeric antigen receptor (CAR) T-cell therapies on the horizon for lymphoma? Barba summarizes the progress made in the development of second generation CD19 CAR T-cell therapies, dual CAR T-cell therapi...

The Lymphoma Hub was pleased to speak with Francesc Bosch, Vall d’Hebron Barcelona Hospital Campus, Barcelona, ES. We asked, How do you choose among different BTK inhibitors for treating CLL? Bosch opens by outlining common BTK inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib, noting that comparable efficacy and activity rates can cause difficulty when determining the most appropriate...

The Lymphoma Hub was pleased to speak with Astrid Pavlovsky, FUNDALEU, Buenos Aires, AR. We asked, What are the latest advances in basal PET/CT for Hodgkin and non-Hodgkin lymphoma? Pavlovsky outlines the progress made in the use of interim positron emission tomography (PET) to guide therapeutic decisions in the last decade, but also notes its limitations, before discussing the latest improvements...

As part of our biannual steering committee meeting, Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, USA, chaired a discussion session on the current and future role of autologous stem cell transplant in the treatment of diffuse large B-cell lymphoma. Many steering committee members felt that this therapy no longer plays an important role in treatment of the disease. Hosted on Acas...

During the ASCO2022 congress, the Lymphoma Hub was pleased to speak with Anita Kumar, Memorial Sloane Kettering Cancer Center, New York, US. We asked, What is on the horizon for the frontline treatment of mantle cell lymphoma (MCL)?  Kumar begins by discussing the historic treatment options for patients with MCL before highlighting that, in the future, clinicians hope to utilize information o...

During the 16th International Conference on Malignant Lymphoma (16-ICML), the Lymphoma Hub spoke with Laurie Sehn, The University of British Columbia, Vancouver, CA, and Grzegorz Nowakowski, Mayo Clinic, Rochester, US. We asked, Is frontline R-CHOP still the standard of care for DLBCL? They begin by revisiting a debate from ICML centering on what the optimal upfront therapy is for DCLB, for S...

During the 2021 ASCO Annual Meeting, the Lymphoma Hub spoke with Catherine S. Diefenbach, Perlmutter Cancer Center, New York, US. We asked, What are the recent advances in antibody-drug conjugates for lymphoma treatment?  Diefenbach summarizes key safety and efficacy data on three antibody therapies across the histological subtypes of lymphoma. These comprise: polatuzumab ...

During the 16th International Conference on Malignant Lymphoma (16-ICML), the Lymphoma Hub spoke with Björn Chapuy, Universitätsmedizin Göttingen, Göttingen, DE, and University Hospital Tübingen, Tübingen, DE. We asked, What is the role of genetic classification in the diagnosis of diffuse large B-cell lymphoma (DLBCL)? Chapuy and de Fend begin by discussing the role of ge...

During the EHA2021 Virtual Congress, the Lymphoma Hub spoke with Ulrich Jäger, Medical University of Vienna, Vienna, AT. We asked, What factors should be considered when deciding whether to refer a patient for chimeric antigen receptor (CAR) T-cell therapy? In this podcast, Jäger discusses the factors that should be considered when selecting patients for CAR T-cell therapy. He analyzes elements of...

During the 2021 ASCO Annual Meeting, the Lymphoma Hub spoke with Michael Wang, MD Anderson Cancer Center, Houston, US, and Peter Martin, Weill Cornell Medicine, New York, US. We asked, What does real-world data tell us about frontline treatment strategies for mantle cell lymphoma (MCL)?    To answer this question, Martin firstly evaluates data from a retrospective study, which inclu...

This is the second episode in a series of podcasts following the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, on the topic of circulating tumor DNA (ctDNA) in the management of lymphoma. The Lymphoma hub asked Reid Merryman, Dana-Farber Cancer Institute, Boston, US, Can circulating tumor DNA (ctDNA) help inform on the suitability of autologous stem cell transplantation...

This is the first episode in a series of podcasts following the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, on the topic of circulating tumor DNA (ctDNA) in the management of lymphoma. The Lymphoma hub asked Davide Rossi, Institute of Oncology Research, Bellinzona, CH, Why should we use ctDNA assessments in lymphoma diagnostics in the future? In this podcast, Rossi tal...

This is the third episode in a series of podcasts following the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, on the topic of circulating tumor DNA (ctDNA) in the management of lymphoma. The Lymphoma hub asked Alex Herrera, City of Hope Comprehensive Cancer Center, Duarte, US, Does ctDNA add value to current prognostic markers for identifying high-risk patients? ctDNA ca...